NO20064395L - Anvendelse av buprenorfin i fremstilling av et medikament - Google Patents

Anvendelse av buprenorfin i fremstilling av et medikament

Info

Publication number
NO20064395L
NO20064395L NO20064395A NO20064395A NO20064395L NO 20064395 L NO20064395 L NO 20064395L NO 20064395 A NO20064395 A NO 20064395A NO 20064395 A NO20064395 A NO 20064395A NO 20064395 L NO20064395 L NO 20064395L
Authority
NO
Norway
Prior art keywords
buprenorphine
medicament
manufacture
provides
over
Prior art date
Application number
NO20064395A
Other languages
English (en)
Other versions
NO329734B1 (no
Inventor
Robert Francis Kaiko
Paul Goldenheim
Robert F Reder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26715643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064395(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20064395L publication Critical patent/NO20064395L/no
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO329734B1 publication Critical patent/NO329734B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
NO20064395A 1997-02-24 2006-09-28 Anvendelse av buprenorfin i fremstilling av et medikament NO329734B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3891997P 1997-02-24 1997-02-24
US08/939,068 US5968547A (en) 1997-02-24 1997-09-29 Method of providing sustained analgesia with buprenorphine
PCT/US1998/003584 WO1998036728A2 (en) 1997-02-24 1998-02-24 Sustained analgesia achieved with buprenorphine

Publications (2)

Publication Number Publication Date
NO20064395L true NO20064395L (no) 1999-10-22
NO329734B1 NO329734B1 (no) 2010-12-13

Family

ID=26715643

Family Applications (11)

Application Number Title Priority Date Filing Date
NO994087A NO322515B1 (no) 1997-02-24 1999-08-24 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20064395A NO329734B1 (no) 1997-02-24 2006-09-28 Anvendelse av buprenorfin i fremstilling av et medikament
NO20074292A NO329838B1 (no) 1997-02-24 2007-08-22 Anvendelse av et polymermatrikslag som inkluderer buprenorfin eller et farmasøytisk akseptabelt salt derav
NO20101190A NO332248B1 (no) 1997-02-24 2010-08-23 Transdermal avleveringsinnretning og anvendelse av buprenorfin i fremstillingen av et medikament.
NO20111441A NO333374B1 (no) 1997-02-24 2011-10-24 Transdermal avleveringsinnretning omfattende buprenorfin
NO20120563A NO333139B1 (no) 1997-02-24 2012-05-14 Transdermal avleveringsinnretning som omfatter buprenorfin og anvendelse av buprenorfin i fremstillingen av et medikament for behandling av smerte
NO20130298A NO334290B1 (no) 1997-02-24 2013-02-26 Transdermal avleveringsinnretning inneholdende buprenorfin for anvendelse ved behandling av smerte samt fremgangsmåte for fremstilling derav
NO20131533A NO337094B1 (no) 1997-02-24 2013-11-18 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20151450A NO340067B1 (no) 1997-02-24 2015-10-26 Buprenorfin transdermal avleveringsanordning for anvendelse ved smertebehandling av en human pasient
NO2016013C NO2016013I1 (no) 1997-02-24 2016-07-18 Buprenorfin; 21-syklopropyl-7µ-[(S)-1-hydroksy-1,2,3-trimetylpropyl]-6,14-endoetano-6,7,8,14-tetrahydrooripavin
NO2017011C NO2017011I1 (no) 1997-02-24 2017-04-04 Buprenorfin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO994087A NO322515B1 (no) 1997-02-24 1999-08-24 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient

Family Applications After (9)

Application Number Title Priority Date Filing Date
NO20074292A NO329838B1 (no) 1997-02-24 2007-08-22 Anvendelse av et polymermatrikslag som inkluderer buprenorfin eller et farmasøytisk akseptabelt salt derav
NO20101190A NO332248B1 (no) 1997-02-24 2010-08-23 Transdermal avleveringsinnretning og anvendelse av buprenorfin i fremstillingen av et medikament.
NO20111441A NO333374B1 (no) 1997-02-24 2011-10-24 Transdermal avleveringsinnretning omfattende buprenorfin
NO20120563A NO333139B1 (no) 1997-02-24 2012-05-14 Transdermal avleveringsinnretning som omfatter buprenorfin og anvendelse av buprenorfin i fremstillingen av et medikament for behandling av smerte
NO20130298A NO334290B1 (no) 1997-02-24 2013-02-26 Transdermal avleveringsinnretning inneholdende buprenorfin for anvendelse ved behandling av smerte samt fremgangsmåte for fremstilling derav
NO20131533A NO337094B1 (no) 1997-02-24 2013-11-18 Anvendelse av buprenorfin i fremstillingen av et transdermalt avleveringssystem for behandling av smerte hos en human pasient
NO20151450A NO340067B1 (no) 1997-02-24 2015-10-26 Buprenorfin transdermal avleveringsanordning for anvendelse ved smertebehandling av en human pasient
NO2016013C NO2016013I1 (no) 1997-02-24 2016-07-18 Buprenorfin; 21-syklopropyl-7µ-[(S)-1-hydroksy-1,2,3-trimetylpropyl]-6,14-endoetano-6,7,8,14-tetrahydrooripavin
NO2017011C NO2017011I1 (no) 1997-02-24 2017-04-04 Buprenorfin

Country Status (22)

Country Link
US (15) US5968547A (no)
EP (9) EP2305191A1 (no)
JP (1) JP2000511936A (no)
KR (1) KR100703101B1 (no)
CN (2) CN1252705A (no)
AT (3) ATE538765T1 (no)
AU (2) AU2004218685B2 (no)
BR (1) BR9815439A (no)
CA (1) CA2276170C (no)
CZ (2) CZ299414B6 (no)
DE (2) DE05011213T1 (no)
DK (4) DK1570823T3 (no)
ES (4) ES2387752T3 (no)
HK (3) HK1096847A1 (no)
HU (3) HUP1500370D0 (no)
IL (4) IL131561A0 (no)
NO (11) NO322515B1 (no)
NZ (1) NZ337386A (no)
PL (1) PL196086B1 (no)
PT (4) PT1731152E (no)
SI (3) SI0964677T1 (no)
WO (1) WO1998036728A2 (no)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114827A1 (en) * 1995-07-28 2002-08-22 Jie Zhang Methods and apparatus for improved administration of analgesics
US20040265353A1 (en) * 1995-07-28 2004-12-30 Zars, Inc. Systems and methods for treating panic attacks
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
EP1280485A4 (en) * 2000-02-29 2006-11-29 Zars Inc TRANSDERMAL STAMP FOR IMPROVED MEDICINE
KR100452972B1 (ko) * 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
AU2001262683A1 (en) * 2000-06-02 2001-12-17 Teijin Limited Buprenorphine-containing patch
GB0021317D0 (en) * 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
DE60141596D1 (de) 2000-10-23 2010-04-29 Euro Celtique Sa Transdermales system zur verabreichung von loratadin und dessen verwendung
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
EP1328273B1 (en) * 2000-10-23 2008-07-02 Euro-Celtique S.A. Felodipine transdermal device and methods
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
WO2002083135A2 (en) * 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
HU229354B1 (en) * 2001-02-16 2013-11-28 Gruenenthal Gmbh Buprenorphine for urinary incontinence therapy
JP2004538256A (ja) * 2001-03-02 2004-12-24 ユーロ−セルティーク，エス．エイ． Ｎ−ブト−３−エチル＝ノルブプレノルフィン及び使用方法
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
PT1416842E (pt) 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JPWO2003014247A1 (ja) * 2001-08-10 2005-01-13 有限会社コスメディ 皮膚用粘着剤及びそれを用いた皮膚用テープ又はシート
AU2002361709A1 (en) * 2001-12-17 2003-06-30 Aryx Therapeutics Analgesic delivery systems and methods of use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
JP2005528359A (ja) * 2002-03-20 2005-09-22 ユーロ−セルティーク エス．エイ． うつ病の治療のためのブプレノルフィンの投与方法
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
CN101455649B (zh) 2002-06-10 2014-02-26 欧洲凯尔特公司 防止所含活性剂被误用的经皮给药器的处置系统
ES2290512T3 (es) * 2002-08-09 2008-02-16 Grunenthal Gmbh Antagonistas del receptor opioide en sistemas transdermicos que contienen buprenorfina.
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
DE60329515D1 (de) * 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
PT1572167E (pt) * 2002-12-13 2008-10-03 Euro Celtique Sa Regime posológico de buprenorfina papa analgesia
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
CN1829482B (zh) 2003-07-25 2012-10-10 欧洲凯尔特公司 治疗依赖戒断的药盒
EP1638492B1 (en) * 2003-07-25 2008-01-02 Euro-Celtique S.A. Preoperative treatment of post operative pain
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
RS50963B (sr) 2004-02-23 2010-10-31 Euro-Celtique S.A. Opioidni transdermalni preparat otporan na zloupotrebu
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
CN101472644B (zh) * 2006-04-13 2014-04-23 纽帕特公司 递送抗偏头痛化合物的透皮方法和系统
WO2007149438A2 (en) 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP2130539A4 (en) * 2007-04-02 2010-05-19 Toyo Boseki THERAPEUTIC TABLET FOR POST-HERPETIC NEURALITY AND METHOD FOR TREATMENT OF POST-HERPETIC NEURALITY
KR101606944B1 (ko) * 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
EP2293751B1 (en) * 2008-06-23 2018-01-10 BioDelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US20110037455A1 (en) * 2009-08-17 2011-02-17 Oren Navot System for measuring electrical power
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
JP5938409B2 (ja) * 2010-09-03 2016-06-22 ゾエティス・ベルジャム・エス・アー 高用量ブプレノルフィン組成物及び使用方法
EP2606895A4 (en) * 2010-10-12 2014-04-02 Univ Wuhan TRANSDERMAL ABSORPTION STAMP OF ANTIVIRAL DRUG AND METHOD FOR PREPARING THE SAME
EP2640389B1 (en) * 2010-11-17 2014-12-31 Hexal AG Transdermal therapeutic system comprising buprenorphine
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
EP2758134B1 (en) * 2011-09-19 2019-05-29 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
TW201338813A (zh) * 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
SG10201710667YA (en) * 2011-12-21 2018-02-27 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
HUE035312T2 (en) * 2012-01-31 2018-05-02 Gruenenthal Gmbh Pharmaceutical patch (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4- b] for transdermal administration of indole] -4-amine
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
JP6434408B2 (ja) * 2012-08-24 2018-12-05 インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 治療剤の経皮送達を増強するための化学組成物および方法
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
JP6370802B2 (ja) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
JP6559121B2 (ja) 2013-06-04 2019-08-14 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システム
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2015369710B2 (en) 2014-12-23 2020-09-17 Vertical Pharmaceuticals, Llc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
BR112020018300A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
US20210251983A1 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine
EP4238669A1 (en) 2022-03-02 2023-09-06 Recutech S.r.o. Method of manufacturing a heat-humidity exchange plate of an enthalpy air-to-air exchanger, a heat-humidity exchange plate and an enthalpy exchanger

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4058599A (en) 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4262003A (en) * 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4119713A (en) 1977-02-09 1978-10-10 Sam Carosio Analgesic and anti-inflammatory composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
DE3330750A1 (de) * 1983-08-26 1985-03-14 Chemische Werke Hüls AG, 4370 Marl Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4636539A (en) 1984-01-30 1987-01-13 Loctite (Ireland) Limited Instant adhesive composition utilizing calixarene accelerators
US4601893A (en) 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
DE3546830C2 (de) 1984-07-23 1995-07-20 Alza Corp Transdermales Abgabesystem zur Verabreichung von Fentanyl
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4834978A (en) 1984-10-01 1989-05-30 Biotek, Inc. Method of transdermal drug delivery
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US5091405A (en) * 1987-01-05 1992-02-25 E. I. Du Pont De Nemours And Company Insecticidal pyrazolines
US5171576A (en) 1987-03-09 1992-12-15 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3812481A1 (de) * 1987-08-26 1989-03-09 Bayer Ag Wasserhaertende polymerzubereitung
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5336210A (en) * 1989-02-28 1994-08-09 Teijin Limited Plaster agent
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
DE3939376C1 (no) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
JP2849937B2 (ja) * 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
KR950005865B1 (ko) * 1990-04-23 1995-06-02 데이진 가부시끼가이샤 첩부제
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
DE4020144A1 (de) * 1990-06-25 1992-01-09 Lohmann Therapie Syst Lts Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen
US5688547A (en) 1990-08-03 1997-11-18 American Cyanamid Company Meal replacement composition and method of weight control
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CN1036343C (zh) 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法
PL166095B1 (pl) 1991-04-03 1995-03-31 Warszawskie Zaklady Farma Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
HUT69390A (en) 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5225440A (en) * 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
ES2137261T3 (es) 1992-05-13 1999-12-16 Alza Corp Administracion transdermica de oxibutinina.
DE69326461T2 (de) 1992-06-11 2000-05-04 Theratech Inc Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4237453C1 (no) 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
JP3489831B2 (ja) * 1993-04-20 2004-01-26 ヘクサル・アクチエンゲゼルシャフト 活性成分パッチ
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE69401945T3 (de) 1993-06-25 2004-09-02 Alza Corp., Palo Alto Einarbeitung eines poly-n-vinylamids in ein transdermales system
WO1995005138A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
AU1575195A (en) 1994-01-20 1995-08-08 Akzo Nobel N.V. New composition of glycoprotein isoforms having follicle stimulating activity
JPH07206710A (ja) * 1994-01-21 1995-08-08 Nitto Denko Corp 経皮投薬用テープ製剤
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5468457A (en) 1994-12-22 1995-11-21 Osram Sylvania Inc. Method of making tungsten-copper composite oxides
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (de) 1995-07-28 1997-02-13 Novartis Ag Transdermales system
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
FR2739731B1 (fr) 1995-10-09 1998-01-02 Axon Cable Sa Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US5792740A (en) 1996-03-08 1998-08-11 Firmenich Sa Fragrant macrocyclic lactones
ATE218328T1 (de) 1996-03-25 2002-06-15 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
AT405158B (de) * 1996-12-04 1999-06-25 Steyr Daimler Puch Ag Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
CA2280033A1 (en) 1997-02-07 1998-08-13 Susan Rako Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU7273898A (en) 1997-04-30 1998-11-24 Human Pheromone Sciences, Inc. Method of fixing fragrances in fragrance composition and other compositions
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5900420A (en) 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
PL341309A1 (en) 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
US6242456B1 (en) 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
ATE254938T1 (de) 1998-03-23 2003-12-15 Elan Corp Plc Vorrichtung zur arzneimittelverarbreichung
WO1999055312A2 (en) 1998-04-29 1999-11-04 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
DE19840758A1 (de) 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
IT1305303B1 (it) 1999-03-10 2001-05-04 Farmigea Spa Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica.
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6554851B1 (en) 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
WO2002017927A1 (en) 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Inc. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
JP2004538256A (ja) 2001-03-02 2004-12-24 ユーロ−セルティーク，エス．エイ． Ｎ−ブト−３−エチル＝ノルブプレノルフィン及び使用方法
JP2005500258A (ja) 2001-03-23 2005-01-06 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Ｇｍ１ガングリオシドを阻害することによる、鎮痛効力を増大し、そして、ニ峰作用性オピオイドアゴニストの有害な興奮性効果を減弱する方法。
DE60235555D1 (de) 2001-04-23 2010-04-15 Euro Celtique Sa Entsorgungssystem für transdermale dosierformen
PT2062573E (pt) * 2001-05-01 2012-01-11 Euro Celtique Sa Sistemas transdérmicos que contêm opióides que resistem a violação
DK1390866T3 (da) 2001-05-22 2010-05-10 Euro Celtique Sa Beholder og fremgangsmåde til afgivelse af transdermale doseringsformer
IL159175A0 (en) 2001-06-04 2004-06-01 Qinetiq Ltd Patterning method
AU2002355266A1 (en) 2001-07-23 2003-02-17 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
AU2002348135A1 (en) 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
JP2005528359A (ja) 2002-03-20 2005-09-22 ユーロ−セルティーク エス．エイ． うつ病の治療のためのブプレノルフィンの投与方法
EP1422230B1 (en) * 2002-11-25 2007-12-26 Chi Mei Foundation Medical Center Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions
PT1572167E (pt) 2002-12-13 2008-10-03 Euro Celtique Sa Regime posológico de buprenorfina papa analgesia
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
EP1638492B1 (en) 2003-07-25 2008-01-02 Euro-Celtique S.A. Preoperative treatment of post operative pain
CN1829482B (zh) 2003-07-25 2012-10-10 欧洲凯尔特公司 治疗依赖戒断的药盒
WO2005018565A2 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
EP1877094A1 (en) 2005-05-03 2008-01-16 Innozen, Inc. Edible film for transmucosal delivery of nutritional supplements
EP1968539A2 (en) 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
EP3067044B1 (en) 2006-07-21 2019-03-27 BioDelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
BRPI0719840A2 (pt) 2006-10-02 2014-11-25 Labtec Gmbh Formas de dosagem de películas não-mucoadesiva
WO2008042508A1 (en) 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
US20080226702A1 (en) 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
EP2293751B1 (en) 2008-06-23 2018-01-10 BioDelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
EP2640389B1 (en) 2010-11-17 2014-12-31 Hexal AG Transdermal therapeutic system comprising buprenorphine

Also Published As

Publication number Publication date
NO20101190L (no) 1999-10-22
EP0964677B1 (en) 2006-08-16
EP1570823A2 (en) 2005-09-07
NO333139B1 (no) 2013-03-11
EP2301493A1 (en) 2011-03-30
EP2305194B1 (en) 2012-05-09
HK1096847A1 (en) 2007-06-15
NO334290B1 (no) 2014-01-27
DK0964677T3 (da) 2006-12-11
PL335306A1 (en) 2000-04-10
US20160220559A1 (en) 2016-08-04
IL207067A (en) 2011-12-29
KR100703101B1 (ko) 2007-04-06
HK1103621A1 (en) 2007-12-28
ATE538765T1 (de) 2012-01-15
NO2017011I1 (no) 2017-04-04
USRE41408E1 (en) 2010-06-29
PT2305194E (pt) 2012-08-14
AU743071B2 (en) 2002-01-17
NO322515B1 (no) 2006-10-16
EP2305193A1 (en) 2011-04-06
HU230608B1 (hu) 2017-03-28
CA2276170C (en) 2007-12-04
NO340067B1 (no) 2017-03-06
HUP1200599A2 (en) 2000-12-28
NO20074292L (no) 1999-10-22
IL131561A0 (en) 2001-01-28
NO329734B1 (no) 2010-12-13
ES2271988T3 (es) 2007-04-16
AU774779B2 (en) 2004-07-08
DE69835584T2 (de) 2007-08-16
NO20130298L (no) 1999-10-22
DK1731152T3 (da) 2013-07-22
ES2423925T3 (es) 2013-09-25
US20140073663A1 (en) 2014-03-13
AU2004218685B2 (en) 2009-01-22
EP0964677A4 (en) 2002-12-18
EP1570823B1 (en) 2011-12-28
EP0964677A1 (en) 1999-12-22
BR9815439A (pt) 2001-10-16
AU6184198A (en) 1998-09-09
SI1570823T1 (sl) 2012-03-30
DE05011213T1 (de) 2007-09-06
AU2925402A (en) 2002-05-16
US5968547A (en) 1999-10-19
EP2301494A1 (en) 2011-03-30
EP2305194A1 (en) 2011-04-06
NO20120563L (no) 1999-10-22
IL201437A (en) 2010-12-30
JP2000511936A (ja) 2000-09-12
SI0964677T1 (sl) 2006-12-31
CA2276170A1 (en) 1998-08-27
DK1570823T3 (da) 2012-02-20
ATE556682T1 (de) 2012-05-15
US20060216340A1 (en) 2006-09-28
EP1731152B1 (en) 2013-05-01
CN1827107B (zh) 2010-05-26
CZ300999A3 (cs) 2000-03-15
HUP1500370D0 (hu) 2000-12-28
ES2387752T3 (es) 2012-10-01
EP2305191A1 (en) 2011-04-06
PL196086B1 (pl) 2007-12-31
AU2008261134A1 (en) 2009-01-15
DK2305194T3 (da) 2012-08-13
CZ2015477A3 (cs) 2015-10-21
NO333374B1 (no) 2013-05-13
NO20131533L (no) 1999-10-22
NO329838B1 (no) 2011-01-10
CN1827107A (zh) 2006-09-06
US9642850B2 (en) 2017-05-09
US20110288112A1 (en) 2011-11-24
AU2004218685A1 (en) 2004-11-04
EP1731152A2 (en) 2006-12-13
WO1998036728A2 (en) 1998-08-27
US20130197020A1 (en) 2013-08-01
US20170056393A1 (en) 2017-03-02
HUP0002342A3 (en) 2001-04-28
KR20000075648A (ko) 2000-12-26
USRE41571E1 (en) 2010-08-24
SI2305194T1 (sl) 2012-10-30
ES2380023T3 (es) 2012-05-07
NO994087D0 (no) 1999-08-24
NO20111441L (no) 1999-10-22
PT964677E (pt) 2006-12-29
NO332248B1 (no) 2012-08-06
NO337094B1 (no) 2016-01-18
HUP0002342A2 (hu) 2000-12-28
PT1731152E (pt) 2013-07-31
US20010002259A1 (en) 2001-05-31
DE69835584D1 (de) 2006-09-28
NO994087L (no) 1999-10-22
US6344212B2 (en) 2002-02-05
HK1153377A1 (en) 2012-03-30
EP1731152A3 (en) 2007-11-14
US20030198675A1 (en) 2003-10-23
USRE41489E1 (en) 2010-08-10
CZ299414B6 (cs) 2008-07-16
CN1252705A (zh) 2000-05-10
ATE336212T1 (de) 2006-09-15
PT1570823E (pt) 2012-03-02
WO1998036728A3 (en) 1998-12-10
NO20151450A1 (no) 1999-10-22
US6231886B1 (en) 2001-05-15
EP2305192A1 (en) 2011-04-06
EP1570823A3 (en) 2006-01-18
IL131561A (en) 2010-05-31
AU2008261134B2 (en) 2012-08-02
US20150157625A1 (en) 2015-06-11
NO2016013I1 (no) 2016-07-18
NZ337386A (en) 2001-06-29
US20030091631A1 (en) 2003-05-15
HU230374B1 (hu) 2016-03-29

Similar Documents

Publication Publication Date Title
NO20064395L (no) Anvendelse av buprenorfin i fremstilling av et medikament
ATE288743T1 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
ES2155931T3 (es) Forma de administracion de un agente activo de liberacion prolongada en banda.
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
FI955583A (fi) Nikotiinia sisältävä nasaalinen lääkkeenjakelukoostumus
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
MXPA01007411A (es) Composiciones y metodos para suministro mucoso.
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
ATE190225T1 (de) Arzneiform zur abgabe von wirkstoffen an wunden
FI972542A (fi) Transdermaalijärjestelmä useamman aktiivisen aineen samanaikaista antamista varten
ATE171869T1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
HK1029277A1 (en) Pharmaceutical coating composition and method of use.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MUNDIPHARMA AS, NO

MK1K Patent expired